PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis

NYSE:PBH • US74112D1019

69.3 USD
-0.91 (-1.3%)
At close: Feb 27, 2026
69.3 USD
0 (0%)
After Hours: 2/27/2026, 8:26:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

PBH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While PBH has a great profitability rating, there are some minor concerns on its financial health. PBH has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • PBH had positive earnings in the past year.
  • PBH had a positive operating cash flow in the past year.
  • PBH had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years PBH had a positive operating cash flow.
PBH Yearly Net Income VS EBIT VS OCF VS FCFPBH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • With an excellent Return On Assets value of 5.34%, PBH belongs to the best of the industry, outperforming 87.05% of the companies in the same industry.
  • With an excellent Return On Equity value of 10.19%, PBH belongs to the best of the industry, outperforming 85.49% of the companies in the same industry.
  • The Return On Invested Capital of PBH (7.55%) is better than 86.53% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for PBH is below the industry average of 12.93%.
Industry RankSector Rank
ROA 5.34%
ROE 10.19%
ROIC 7.55%
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
PBH Yearly ROA, ROE, ROICPBH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

1.3 Margins

  • PBH has a Profit Margin of 16.90%. This is amongst the best in the industry. PBH outperforms 89.12% of its industry peers.
  • In the last couple of years the Profit Margin of PBH has grown nicely.
  • PBH's Operating Margin of 30.34% is amongst the best of the industry. PBH outperforms 94.30% of its industry peers.
  • In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 56.12%, PBH is in the better half of the industry, outperforming 68.91% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
Industry RankSector Rank
OM 30.34%
PM (TTM) 16.9%
GM 56.12%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
PBH Yearly Profit, Operating, Gross MarginsPBH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PBH is destroying value.
  • PBH has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PBH has been reduced compared to 5 years ago.
  • Compared to 1 year ago, PBH has an improved debt to assets ratio.
PBH Yearly Shares OutstandingPBH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PBH Yearly Total Debt VS Total AssetsPBH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 2.59 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.59, PBH is in the better half of the industry, outperforming 67.36% of the companies in the same industry.
  • The Debt to FCF ratio of PBH is 3.95, which is a good value as it means it would take PBH, 3.95 years of fcf income to pay off all of its debts.
  • PBH has a Debt to FCF ratio of 3.95. This is amongst the best in the industry. PBH outperforms 88.08% of its industry peers.
  • PBH has a Debt/Equity ratio of 0.58. This is a neutral value indicating PBH is somewhat dependend on debt financing.
  • The Debt to Equity ratio of PBH (0.58) is worse than 64.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF 3.95
Altman-Z 2.59
ROIC/WACC0.87
WACC8.64%
PBH Yearly LT Debt VS Equity VS FCFPBH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 3.11 indicates that PBH has no problem at all paying its short term obligations.
  • PBH has a Current ratio (3.11) which is in line with its industry peers.
  • PBH has a Quick Ratio of 1.93. This is a normal value and indicates that PBH is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of PBH (1.93) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 1.93
PBH Yearly Current Assets VS Current LiabilitesPBH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.92% over the past year.
  • PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
  • The Revenue has decreased by -1.31% in the past year.
  • PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
Revenue 1Y (TTM)-1.31%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.28% on average over the next years.
  • The Revenue is expected to grow by 0.71% on average over the next years.
EPS Next Y1.56%
EPS Next 2Y3.7%
EPS Next 3Y3.57%
EPS Next 5Y4.28%
Revenue Next Year-2.45%
Revenue Next 2Y-0.18%
Revenue Next 3Y0.52%
Revenue Next 5Y0.71%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PBH Yearly Revenue VS EstimatesPBH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
PBH Yearly EPS VS EstimatesPBH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • PBH is valuated correctly with a Price/Earnings ratio of 15.47.
  • PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 87.56% of the companies in the same industry.
  • PBH is valuated rather cheaply when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • PBH is valuated correctly with a Price/Forward Earnings ratio of 14.23.
  • Based on the Price/Forward Earnings ratio, PBH is valued cheaply inside the industry as 85.49% of the companies are valued more expensively.
  • PBH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.05.
Industry RankSector Rank
PE 15.47
Fwd PE 14.23
PBH Price Earnings VS Forward Price EarningsPBH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaply inside the industry as 86.01% of the companies are valued more expensively.
  • 89.64% of the companies in the same industry are more expensive than PBH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.27
EV/EBITDA 11.7
PBH Per share dataPBH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)9.93
PEG (5Y)1.74
EPS Next 2Y3.7%
EPS Next 3Y3.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PBH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRESTIGE CONSUMER HEALTHCARE

NYSE:PBH (2/27/2026, 8:26:05 PM)

After market: 69.3 0 (0%)

69.3

-0.91 (-1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners108.83%
Inst Owner Change0.3%
Ins Owners1.31%
Ins Owner Change-0.48%
Market Cap3.28B
Revenue(TTM)1.10B
Net Income(TTM)186.50M
Analysts84
Price Target78.95 (13.92%)
Short Float %4.68%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.91%
Min EPS beat(2)-1.36%
Max EPS beat(2)9.18%
EPS beat(4)2
Avg EPS beat(4)0.63%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)4
Avg EPS beat(8)-0.63%
EPS beat(12)6
Avg EPS beat(12)-46.73%
EPS beat(16)10
Avg EPS beat(16)-34.55%
Revenue beat(2)1
Avg Revenue beat(2)2.53%
Min Revenue beat(2)-0.49%
Max Revenue beat(2)5.55%
Revenue beat(4)2
Avg Revenue beat(4)0.29%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)-0.13%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.05%
EPS NQ rev (3m)-1.13%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)0.88%
Revenue NQ rev (1m)-2.24%
Revenue NQ rev (3m)-2.61%
Revenue NY rev (1m)-0.45%
Revenue NY rev (3m)-0.09%
Valuation
Industry RankSector Rank
PE 15.47
Fwd PE 14.23
P/S 2.97
P/FCF 12.27
P/OCF 11.85
P/B 1.79
P/tB N/A
EV/EBITDA 11.7
EPS(TTM)4.48
EY6.46%
EPS(NY)4.87
Fwd EY7.03%
FCF(TTM)5.65
FCFY8.15%
OCF(TTM)5.85
OCFY8.44%
SpS23.32
BVpS38.66
TBVpS-22.26
PEG (NY)9.93
PEG (5Y)1.74
Graham Number62.43
Profitability
Industry RankSector Rank
ROA 5.34%
ROE 10.19%
ROCE 9.98%
ROIC 7.55%
ROICexc 7.69%
ROICexgc 61.8%
OM 30.34%
PM (TTM) 16.9%
GM 56.12%
FCFM 24.21%
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF 3.95
Debt/EBITDA 2.88
Cap/Depr 31.31%
Cap/Sales 0.86%
Interest Coverage 7.66
Cash Conversion 75.79%
Profit Quality 143.26%
Current Ratio 3.11
Quick Ratio 1.93
Altman-Z 2.59
F-Score5
WACC8.64%
ROIC/WACC0.87
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
EPS Next Y1.56%
EPS Next 2Y3.7%
EPS Next 3Y3.57%
EPS Next 5Y4.28%
Revenue 1Y (TTM)-1.31%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%
Revenue Next Year-2.45%
Revenue Next 2Y-0.18%
Revenue Next 3Y0.52%
Revenue Next 5Y0.71%
EBIT growth 1Y1.3%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year5.29%
EBIT Next 3Y3.49%
EBIT Next 5Y2.82%
FCF growth 1Y15.15%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y14.78%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%

PRESTIGE CONSUMER HEALTHCARE / PBH FAQ

What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PBH.


Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?

ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.


What is the profitability of PBH stock?

PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.


What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?

The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.56% in the next year.